StabilGuard®Immunoassay Stabilizer (BSA-Free)

Added to your cart

StabilGuard®Immunoassay Stabilizer (BSA-Free)

Cart subtotal: £0.00

View cart (0) Checkout

#SKU SG01-1000

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team
Surmodics logo.jpg

Product Details

StabilGuard® Immunoassay Stabilizer (BSA-Free) maintains the activity of antibodies and other biomolecules adsorbed or immobilized to solid substrates. It is easily incorporated into most assay protocols as the blocking solution, and minimal incubation is required.

SG01-1000

More information

Attributes

Description

  • Reference Texts
  • DAVIDSON, A. et al., 2008. Lack of correlation between antibody titers to fibrinogen-binding protein of Streptococcus equi and persistent carriers of strangles. Journal of veterinary diagnostic investigation: official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 20(4), 457–462OPALKA, D. et al., 2010. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clinical and vaccine immunology: CVI, 17(5), 818–827
  • Specification
  • Protein: NoneProduct Buffer: PBSpH: 6.6‐7.2
  • Recommended Use
  • Lateral Flow / Elisa / CLIA
  • Preservatives
  • None
  • Storage
  • 2 - 8°C or room temperature

Technical Documents

MSDS-SG01 (153.3KB)

Product insert-SG01 (189.79KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox